Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase

• by Alexa B. Kimball, Konrad T. Sawicki, Lindsay Ackerman, Hermenio Lima, Evangelos J. Giamarellos-Bourboulis, Tianyu Zhan, Leonidas Drogaris, Yihua Gu, Christine M. Lee, Mona Akbari, David A. Williams, Falk G. Bechara

• May 1, 2026

A Comprehensive Review of Local Treatment Options for Hidradenitis Suppurativa: Current Strategies and Challenges

• by Elisa Molinelli, Davide Febi, Edoardo De Simoni, Maria Luisa Dragonetti, Irene Richiardi, Matteo Candelora, Daisy Gambini, Sara Belleggia, Guendalina Lucarini, Oriana Simonetti

• March 18, 2026

Psychiatric and Psychological Care Utilization Among Patients with Atopic Dermatitis, Hidradenitis Suppurativa, and Psoriasis: Insights from a Propensity-Matched Real-World Cohort Analysis

• by Marta Szepietowska, Piotr K. Krajewski, Przemyslaw Pacan, Anna Wojas-Pelc, Jacek C. Szepietowski, Andrzej K. Jaworek

• March 3, 2026

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

• by Kerri Miller

• April 16, 2026

• 3 min